Roshan Shrestha, MD
Gastroenterology · Atlanta, GANPI 1427191782
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $252,680 of the $317,268 with a category attached, or 79.6%. 28 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 45.8% of the total. Reporting peaked in 2019 at $133,347 and has fallen 92.7% since, to $9,791 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 521 payments — averaging $608.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145K
- Gilead$133K
- Boston Scientific$19K
- Dova Pharmaceuticals$14K
- Intercept Pharmaceuticals, Inc.$1K
- Ambu Inc.$1K
- plus $4K from 22 others
Across 1 payment — averaging $6207.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$6K
What the payments were for
- Consulting fees$7500%
- Speaking & faculty fees$252,68080%
- Travel & lodging$39,66113%
- Food & beverage$24,1548%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 175 | $145,370 |
| Gilead | 162 | $133,131 |
| Boston Scientific | 96 | $18,827 |
| Dova Pharmaceuticals | 14 | $13,590 |
| Intercept Pharmaceuticals, Inc. | 24 | $1,238 |
| Ambu Inc. | 6 | $1,050 |
| Shionogi Inc | 2 | $875 |
| Delcath Systems | 3 | $504 |
| Biocompatibles, Inc. | 3 | $412 |
| Sirtex Medical Inc | 2 | $313 |
| Medtronic | 2 | $307 |
| W. L. Gore & Associates, Inc. | 3 | $241 |
| AbbVie | 6 | $198 |
| Echosens North America, Inc. | 1 | $149 |
| Histosonics, Inc. | 1 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Medical Device Business Services, Inc. | 1 | $124 |
| Olympus America Inc. | 1 | $116 |
| Astellas Pharma US Inc | 5 | $100 |
| Cook Medical LLC | 1 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $95 |
| Perspectum Diagnostics Ltd | 1 | $72 |
| Intra-sana Laboratories | 1 | $52 |
| AstraZeneca | 3 | $48 |
| Orphalan Inc | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| QOL Medical, LLC | 1 | $18 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$141,864
- Vemlidy$61,387
- Epclusa$45,166
- DOPTELET$13,360
- SPYGLASS$9,977
- TheraSphere Y90 Glass Microspheres 10 GBq$1,830
- EXALT Model D$1,725
- GENERAL - THERAPIES$1,330
- OCALIVA$937
- Mulpleta$875
- THERASPHERE$733
- Hepzato Kit$504
- THERASPHERE-BIO$412
- GENERAL - BILIARY DEVICES$347
- EXALT$327
- SIR-Spheres Microspheres$313
- GI Genius$289
- FibroScan$149
- GENERAL VASCULAR INTERVENTION$145
- ACQUIRE$138
How this compares
$317,268 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 56 | $162,338 |
| VemlidyTenofovir Alafenamide | 35 | $62,226 |
| Everolimus | 13 | $24,932 |
| Tacrolimus | 75 | $18,713 |
| Ursodiol | 84 | $14,493 |
| Sirolimus | 14 | $7,135 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $3,230 |
| Mycophenolate Mofetil | 30 | $2,556 |
| Tenofovir Disoproxil Fumarate | 16 | $1,092 |
| Lactulose | 19 | $824 |
| Bumetanide | 15 | $511 |
| Pantoprazole Sodium | 24 | $355 |
| Prednisone | 40 | $295 |
| Spironolactone | 21 | $199 |
| Amiloride Hcl | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $145,370 | $162,33856 claims |
| GileadVemlidy | $133,131 | $62,22635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Atlanta
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Hetal KarsanAtlanta$314K
- Marc SonenshineAtlanta$201K
- Julia LiuAtlanta$163K
- Huiming HonAtlanta$159K
- Norman GitlinAtlanta$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.